Skip to main content

Table 3 Comparison of commonly used allogeneic NK cell sources

From: NK cell-based cancer immunotherapy: from basic biology to clinical development

NK source Advantages Limitations
PB-NK cells Relatively easy to collect
Good in vivo expansion
Good clinical track record
Heterogeneous cell population
Challenging to genetically modify
Can only give one dose
UB-NK cells NK Progenitors and CD34 + present
Higher percentage of NK cells
The ability to cryopreserve UCB
Heterogeneous cell population
NK92 cells Defined, homogeneous cell population
Easy to expand
Easy to genetically modify
Can give multiple doses
Tumor cells Irradiated
Lack certain receptors, e.g., CD16
limited in vivo expansion
iPSC-NK cells Defined, homogeneous cell population
Circumvent issues with donor sourced cells (donor selection, contaminating T, B)
Potential for in depth preclinical testing
Defined genetic makeup
Easy to genetically modify at iPSC stage
Can give multiple doses
Can engineer multiple enhancements
Don’t need to irradiate- good in vivo survival
Suitable for “off-the-shelf” multicancer NK cell therapy
More complicated to produce